<DOC>
	<DOCNO>NCT02019420</DOCNO>
	<brief_summary>This 1:1 ratio , randomize , double-blind , double-dummy , multicenter , global Phase 3 study tedizolid phosphate ( TR-701 FA ) 200 mg intravenous ( IV ) daily 7 day versus linezolid ( Zyvox® , Zyvoxid® , etc ) 600 mg IV every 12 hour 10 day treatment ventilate participant presumed gram-positive hospital-acquired bacterial pneumonia ( HABP ) ventilator-associated bacterial pneumonia ( VABP ) . Participants concurrent gram-positive bacteremia receive 14 day active therapy either treatment arm . Approximately 300 site participate . Ventilated participant HABP/VABP cause presumed gram-positive pathogen ( ) baseline , determine positive Gram stain , randomize 1:1 study drug treatment .</brief_summary>
	<brief_title>Tedizolid Phosphate ( TR-701 FA ) v Linezolid Treatment Nosocomial Pneumonia ( MK-1986-002 )</brief_title>
	<detailed_description>The primary objective determine noninferiority ( NI ) all-cause mortality ( ACM ) within 28 day randomization IV tedizolid phosphate compare IV linezolid Intent Treat ( ITT ) Analysis Set ventilate participant presume gram-positive HABP gram-positive VABP , collectively define ventilate nosocomial pneumonia ( VNP ) .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Requires IV antibiotic therapy diagnosis ventilate nosocomial pneumonia Grampositive bacteria respiratory Gram stain Pneumonia viral , fungal parasitic etiology Structural lung abnormality Immunosuppression Previous antibiotic &gt; 24 hour Expected survival &lt; 72 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pneumonia</keyword>
	<keyword>Tedizolid Phosphate</keyword>
	<keyword>TR-701</keyword>
</DOC>